AstraZeneca PLC · LSE:AZN
AstraZeneca — Shareholder Meeting (April 2010)
38 slides from AstraZeneca's shareholder meeting presentation, Apr 29, 2010
Slide 1: 2010 Annual General Meeting
AstraZeneca st a e eca PLC C 2010 Annual General Meeting 29 April 2010
Slide 2: Louis Schweitzer, Chairman
AstraZeneca st a e eca PLC C 2010 Annual General Meeting Louis Schweitzer Chairman
Slide 3: Rudy Markham, Non-Executive Director
AstraZeneca st a e eca PLC C 2010 Annual General Meeting Rudy Markham Non-Executive Director
Slide 4: Michele Hooper, Non-Executive Director
AstraZeneca st a e eca PLC C 2010 Annual General Meeting Michele Hooper Non-Executive Director
Slide 5: John Buchanan, Non-Executive Director
AstraZeneca st a e eca PLC C 2010 Annual General Meeting John Buchanan Non-Executive Director
Slide 6: Simon Lowth, Chief Financial Officer
AstraZeneca st a e eca PLC C 2010 Annual General Meeting Simon Lowth Chief Financial Officer
Slide 7: David Brennan, Chief Executive Officer
AstraZeneca st a e eca PLC C 2010 Annual General Meeting David Brennan Chief Executive Officer
Slide 8: Jean-Philippe Courtois, Non-Executive Director
AstraZeneca st a e eca PLC C 2010 Annual General Meeting Jean-Philippe Courtois Non-Executive Director
Slide 9: Bo Angelin, Non-Executive Director
AstraZeneca st a e eca PLC C 2010 Annual General Meeting Bo Angelin Non-Executive Director
Slide 10: Dame Nancy Rothwell, Non-Executive Director
AstraZeneca st a e eca PLC C 2010 Annual General Meeting Dame Nancy Rothwell Non-Executive Director
Slide 11: Marcus Wallenberg, Non-Executive Director
AstraZeneca st a e eca PLC C 2010 Annual General Meeting Marcus Wallenberg Non-Executive Director
Slide 12: John Varley, Non-Executive Director
AstraZeneca st a e eca PLC C 2010 Annual General Meeting John Varley Non-Executive Director
Slide 13: Jane Henney, Non-Executive Director
AstraZeneca st a e eca PLC C 2010 Annual General Meeting Jane Henney Non-Executive Director
Slide 14: Annual General Meeting 2010 - Louis Schweitzer, Chairman
Annual ua Ge General e a Meeting eet g 2010 Louis Schweitzer Chairman
Slide 15: 2009 financial highlights
2009 financial highlights 2009 2008 Actual CER $m $m growth growth Sales 32,804 31,601 +4% +7% Core operating profit 13,621 10,958 +24% +23% Core earnings per share $6 32 $6.32 $5 10 $5.10 +24% +23% • 10 medicines with sales over $$1 billion each • Net debt reduced by $7.7 billion 15
Slide 16: Business environment
Business environment Nominal GDP % Compound Annual Growth Rate 04-09 09-14E 14% 10% Asia 3,450m , Middle East, 12% 8% Africa 1,450m Latin 12% 7% America 550m Eastern 14% 9% Europe 400m ~85% of the world’s population lives in emerging markets W Europe / 4% 4% N A America i 750m All real economic grow
Slide 17: Our vision
Our vision AstraZeneca is Foc sed Focused Integrated I Innovation-driven ti di Gl b l Global OUR VALUES 17
Slide 18: Annual General Meeting 2010
Annual ua Ge General e a Meeting eet g 2010
Slide 19: David Brennan, CEO
Annual ua Ge General e a Meeting eet g 2010 David Brennan CEO
Slide 20: 2009 operational highlights
2009 operational highlights • Supply chain excellence • Product launches - Restored US Toprol-XL supply - ONGLYZA – with Bristol-Myers Squibb - H1N1 pandemic vaccine - Iressa in EU • Four major regulatory filings • Development projects - Brilinta - 11 in Phase III - Certriad – with Abbott - 34 in Ph
Slide 21: Headline results: 1Q 2010
Headline results: 1Q 2010 2010 2009 Actual CER $ $m $ $m growth th growth th Revenue 8,576 7,701 +11% 11% +7% 7% Core Operating Profit 3,857 3,362 +15% +10% Reported EPS $1.91 $1.48 +29% +23% Core EPS $2.03 $1.58 +28% +23% 21
Slide 22: Regional revenue performance: 1Q2010
Regional revenue performance: 1Q2010 2010 CER $m growth Total Revenue 8 576 8,576 +7% US 3,698 , +2% Western Europe 2,465 +7% Established ROW 1,156 +12% Emerging ROW 1,257 +19% 22
Slide 23: Key Brand revenue summary: 1Q2010
Key Brand revenue summary: 1Q2010 2010 CER CER $m % $m Nexium 1,239 - (2) Seroquel 1,307 +13 151 Crestor 1,300 +27 264 Arimidex 511 +7 7 32 Symbicort 701 +29 148 23
Slide 24: Headline results: 1Q 2010
Headline results: 1Q 2010 2010 2009 Actual CER $ $m $ $m growth th growth th Revenue 8,576 7,701 +11% 11% +7% 7% Core Operating Profit 3,857 3,362 +15% +10% Reported EPS $1.91 $1.48 +29% +23% Core EPS $2.03 $1.58 +28% +23% Restructuring/Synergy ($0.05) ($0.03) MedImmune/Merck amortisation ($0.07) ($
Slide 25: Strategic review
Strategic review Making the most meaningful difference to patient health through great medicines Business Pipeline Business Culture and shape growth behaviour
Slide 26: People
AstraZeneca People • Bruno Angelici, Executive Vice-President, International Sales and Marketing Organisation • Mene e e Pangalos, a ga os, Executive Vice-President, Innovative Medicines 26
Slide 27: AstraZeneca in 1999 and 2009
AstraZeneca AstraZeneca in 1999 • 47,000 employees • Healthcare revenue: $15bn - Only 6% of sales from emerging markets - 2 products >$1bn annual sales AstraZeneca in 2009 • 63,000 employees • Healthcare revenue: $32.8bn - Emerging markets = 13% of sales - 10 products >$1bn annual sales 27
Slide 28: Annual General Meeting 2010
Annual ua Ge General e a Meeting eet g 2010
Slide 29: Resolutions
Resolutions 1. To receive the Company’s Accounts 6. To approve the Directors’ Remuneration and the Reports of the Directors and Report for the year ended 31 December 2009 Auditor for the yyear ended 31 December 2009 7. To authorise limited EU political donations 2. To confirm dividends 8. To authori
Slide 30: Polling card and results announcement
AstraZeneca st a e eca PLC C 2010 Annual General Meeting • Please place your completed Polling Card in one of the boxes as you leave the meeting room • We expect to announce the results of the poll later today • The results of the poll will also be published in the Investors section of our website,
Slide 31: Resolutions
Resolutions 1. To receive the Company’s Accounts 6. To approve the Directors’ Remuneration and the Reports of the Directors and Report for the year ended 31 December 2009 Auditor for the yyear ended 31 December 2009 7. To authorise limited EU political donations 2. To confirm dividends 8. To authori
Slide 32: Thank you for attending
AstraZeneca st a e eca PLC C 2010 Annual General Meeting Thank you for attending and have a safe journey home
Slide 33: Annual General Meeting April 2010
AstraZeneca st a e eca PLC C 2010 Annual General Meeting 29 April 2010
Slide 34: Meeting adjourned notice
AstraZeneca st a e eca PLC C 2010 Annual General Meeting The meeting has been adjourned and will restart at 3.00pm. The main venue at the Renaissance Chanceryy Court Hotel is nearing capacity and some attendees are making their way to an overflow venue a short distance away. Thank you for your patie
Slide 35: Annual General Meeting April 2010
AstraZeneca st a e eca PLC C 2010 Annual General Meeting 29 April 2010
Slide 36: AZIP – tests assessed annually
AZIP – 2 tests assessed annually The years award will lapse fully if either of the key performance hurdles fails to be satisfied in any year during the performance period. Illustration for 2010 awards – annual dividend of at least $2.30 – dividend cover must be at least 1.5x Performance Period Holdi
Slide 37: CEO remuneration vs. market
CEO remuneration vs. market CEO’s remuneration (EV) vs UK FTSE 30 and US pharmaceutical market practice Remuneration positioning: moderate vs UK, and in the lower quartile relative to AZ’s international peer group £10,000,000 £9,000,000 £8,000,000 £7,000,000 £6,000,000 £5,000,000 £4,000,000 £3,000,0
Slide 38: CFO remuneration vs. market
CFO remuneration vs. market CFO’s remuneration (EV) vs UK FTSE 30 and US pharmaceutical market practice Remuneration positioning: median vs UK, and in the lower quartile relative to AZ’s international peer group £3,500,000 £3,000,000 £2,500,000 £2,000,000 LTI £1 500 000 £1,500,000 A Annual lBBonus B